Bone Health in Gynecologic Cancers-does FOSAVANCE Help?
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Women who undergo bilateral oophorectomy and receive chemotherapy are at risk of increased
bone loss. At present, despite having a risk factor profile that fits the indications for
assessment and treatment there are no routine interventions in this patient population i.e.,
the standard treatment is no treatment. We hope to identify whether or not an intervention
may be favorable in these women and change the standard of care in this vulnerable
population.
Hypothesis:
Weekly therapy with alendronate + vitamin D (FOSAVANCE) will improve bone health as measured
by DEXA scans in women with gynecologic malignancies undergoing chemotherapy as compared with
patients receiving placebo.